Connect with us

Health

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity – News-Medical.Net

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome…

Published

on

Article feature image

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv* server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.
New approaches to spike-based vaccines
Both the viral spike antigen and its receptor-binding domain (RBD), which elicit highly potent neutralizing…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Mild Covid very unlikely to cause lasting heart damage: Study – Gulf News
Scientists launch search for genetic test to spot killer prostate cancer – The Guardian